StockNews.com initiated coverage on shares of Agile Therapeutics (NASDAQ:AGRX – Free Report) in a research report sent to investors on Sunday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Agile Therapeutics Stock Performance
Shares of AGRX stock opened at $1.46 on Friday. Agile Therapeutics has a 12-month low of $0.20 and a 12-month high of $2.63. The firm’s 50 day moving average is $1.24 and its 200 day moving average is $0.81. The stock has a market capitalization of $9.99 million, a P/E ratio of -0.40 and a beta of 1.58.
Agile Therapeutics (NASDAQ:AGRX – Get Free Report) last issued its quarterly earnings results on Monday, August 12th. The specialty pharmaceutical company reported ($0.68) earnings per share for the quarter. The firm had revenue of $5.58 million for the quarter.
Institutional Inflows and Outflows
About Agile Therapeutics
Agile Therapeutics, Inc, a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.
Featured Articles
- Five stocks we like better than Agile Therapeutics
- What is the Nikkei 225 index?
- Target Hits the Mark: Q2 Earnings Exceed Expectations
- Stock Average Calculator
- Is Tesla’s Rebound Just Starting? Why You Should Consider Buying
- Stock Market Sectors: What Are They and How Many Are There?
- Stanley Druckenmiller’s Latest Bet: MELI—Should You Follow Suit?
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.